Eton Pharmaceuticals (NASDAQ:ETON) Stock Rating Upgraded by ValuEngine

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.

Several other analysts have also issued reports on the company. Zacks Investment Research lowered Eton Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, November 22nd. B. Riley assumed coverage on shares of Eton Pharmaceuticals in a research note on Friday, September 20th. They set a “buy” rating and a $13.50 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price objective (up from $18.00) on shares of Eton Pharmaceuticals in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $13.75.

ETON opened at $5.98 on Wednesday. The stock has a market capitalization of $106.49 million and a P/E ratio of -1.03. The stock has a 50-day moving average price of $6.02 and a 200-day moving average price of $6.60. Eton Pharmaceuticals has a 12-month low of $5.13 and a 12-month high of $10.20.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, November 14th. The company reported ($0.28) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.05). Research analysts expect that Eton Pharmaceuticals will post -1.13 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of ETON. First Allied Advisory Services Inc. purchased a new stake in Eton Pharmaceuticals during the third quarter valued at about $228,000. First Trust Advisors LP bought a new position in shares of Eton Pharmaceuticals during the third quarter valued at about $155,000. BlackRock Inc. increased its holdings in shares of Eton Pharmaceuticals by 181.2% in the second quarter. BlackRock Inc. now owns 26,092 shares of the company’s stock worth $206,000 after buying an additional 16,813 shares during the period. Vanguard Group Inc. increased its holdings in shares of Eton Pharmaceuticals by 6.7% in the second quarter. Vanguard Group Inc. now owns 28,762 shares of the company’s stock worth $227,000 after buying an additional 1,800 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Eton Pharmaceuticals by 122.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,139 shares of the company’s stock worth $25,000 after buying an additional 1,728 shares during the period. 12.80% of the stock is owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

Featured Story: What are defining characteristics of a correction?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.